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Dyspnea Assessment and Pulmonary Hypertension
in Patients With Systemic Sclerosis: Utility of the
University of California, San Diego, Shortness of
Breath Questionnaire
LORINDA CHUNG,1 HUBERT CHEN,2 DINESH KHANNA,3 AND VIRGINIA D. STEEN4
Objective. The University of California in San Diego Shortness of Breath Questionnaire (UCSD SOBQ) has been used to
assess dyspnea-related activity limitation in patients with airway and parenchymal lung disease. We sought to assess the
construct validity and responsiveness of the UCSD SOBQ in systemic sclerosis (SSc; scleroderma) patients with incident
pulmonary hypertension (PH) and those at high risk of developing PH.
Methods. We used data from 179 patients enrolled in the Pulmonary Hypertension Assessment and Recognition of
Outcomes in Scleroderma Registry with pre-PH (defined by criteria on pulmonary function tests and/or echocardiogram)
or definite PH with mean pulmonary artery pressure >25 mm Hg by right-sided heart catheterization within 6 months of
enrollment. For this analysis, we included those subjects with complete data for self-reported measures at baseline and
at 12 months.
Results. At baseline, the UCSD SOBQ had strong correlations in the expected direction with the disability index (DI) of
the Health Assessment Questionnaire (HAQ) (r  0.71, P < 0.0001), dyspnea assessment by visual analog scale (r  0.71,
P < 0.0001), and the Short Form 36 (SF-36) health survey physical component summary (PCS) score (r  0.77, P <
0.0001), as well as a moderate correlation with the 6-minute walk test distance (r  0.33, P < 0.0001), Borg dyspnea
score (r  0.47, P < 0.0001), and diffusing capacity of carbon monoxide (r  0.33, P < 0.0001). Change in the UCSD
SOBQ at 12 months correlated in the expected direction with change in the HAQ DI (r  0.54, P < 0.0001) and change
in the SF-36 PCS (r  0.44, P < 0.0001). Multivariate analysis adjusting for age, sex, and race identified male sex as a
significant predictor of death (odds ratio [OR] 7.00, 95% confidence interval [95% CI] 1.55–31.76), while the UCSD SOBQ
showed a strong trend toward significance (OR 1.82, 95% CI 0.97–3.41).
Conclusions. The UCSD SOBQ demonstrates good construct validity and responsiveness to change in SSc patients with
pulmonary vascular disease.
INTRODUCTION
Systemic sclerosis (SSc; scleroderma) is a chronic autoim-
mune disease characterized by fibrosis of the skin and
internal organs and widespread vasculopathy. Pulmonary
involvement, including interstitial lung disease (ILD) and
pulmonary hypertension (PH), is common in patients with
SSc and is the most common cause of death in recent years
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(1). PH, defined as a right ventricular systolic pressure
(RVSP) on transthoracic echocardiogram (TTE) of 40 mm
Hg, is observed in 28% of patients (2) and can be related to
precapillary pulmonary arterial hypertension (PAH), pul-
monary veno-occlusive disease, or secondary to left-sided
heart disease or severe ILD. The prevalence of PAH, con-
firmed by right-sided heart catheterization (RHC), has been
estimated between 8–12% (3,4). Despite the availability
of several PAH-specific therapies, patients with SSc-PAH
experience poorer survival than patients with idiopathic
PAH or other connective tissue disease (CTD)–associated
PAH (5). The Pulmonary Hypertension Assessment and
Recognition of Outcomes in Scleroderma (PHAROS) reg-
istry was established in 2006 to assess outcomes of pa-
tients at high risk of developing PAH and of those with
incident disease (6). The premise of PHAROS is that early
detection and close monitoring of PAH in patients with
SSc could improve health-related outcomes.
Validated measures to monitor PAH disease progression
and severity are necessary for clinical trials and the rou-
tine care of patients with SSc-PAH. Although the 6-minute
walk test has been partially validated in SSc-PAH, and is
routinely used as a primary outcome in PAH clinical trials
(7), musculoskeletal and other systemic comorbidities
complicate the interpretation of this test in patients with
SSc. Brain natriuretic peptide (BNP) and N-terminal (NT)
proBNP levels correlate with hemodynamics and exercise
capacity in patients with SSc-PAH (8,9), but require a
blood draw and are affected by renal insufficiency. The
University of California in San Diego (UCSD) Shortness of
Breath Questionnaire (SOBQ) is a 24-item measure that
assesses self-reported shortness of breath while perform-
ing activities of daily living (10). It has been validated
and used extensively in studies of patients with obstruc-
tive lung disease and restrictive lung disease (11,12). We
chose this particular questionnaire because it focuses on
dyspnea-limited activities rather than functional limita-
tions. A recent study found that the UCSD SOBQ was
strongly correlated with physical function and psycholog-
ical well-being, and strongly inversely correlated with
forced vital capacity (FVC) and diffusing capacity of car-
bon monoxide (DLCO) in patients with CTD-associated ILD
(13). The utility of the UCSD SOBQ in the assessment of
dyspnea in patients with pulmonary vascular disease has
not yet been evaluated. We sought to assess the construct
validity and responsiveness to change of the UCSD SOBQ
in SSc patients enrolled in the PHAROS registry with
incident PH or who are at high risk of developing PH. We
hypothesized that the UCSD SOBQ would correlate in the
anticipated direction with other validated patient-reported
measures of disability and dyspnea, as well as with clini-
cal measures of disease severity, in such a way to provide
preliminary validity of the instrument for use in clinical
trials of pulmonary vascular disease in SSc patients.
PATIENTS AND METHODS
PHAROS is a longitudinal prospective registry involving
22 US scleroderma centers. Each participating center ob-
tained institutional review board approval prior to patient
enrollment, and all patients provided written informed
consent prior to enrollment. The baseline characteristics
and study design for PHAROS are described elsewhere (6).
The PHAROS registry enrolls SSc patients at high risk
of developing PH (pre-PH) or those with definite PH diag-
nosed by RHC within 6 months of enrollment. Pre-PH pa-
tients must fulfill one of the following 3 criteria: 1) RVSP
on TTE of 40 mm Hg, 2) FVC 70% predicted and DLCO
55% predicted, or 3) FVC/DLCO ratio of 1.6. RHC was
obtained in pre-PH patients as clinically indicated and
determined by the treating physician. Patients with defi-
nite PH must have a mean pulmonary artery pressure
(mPAP) of 25 mm Hg at rest on RHC performed within
the 6 months prior to enrollment into the registry.
The investigator at each site confirmed the World Health
Organization (WHO) group classification according to the
2009 Dana Point Classification Criteria for PH: 1) WHO
group I: PAH: mPAP 25 mm Hg on RHC with pulmonary
capillary wedge pressure (PCWP) 15 mm Hg without
significant ILD, defined as an FVC 65% predicted and no
or only mild fibrosis on high-resolution computed tomog-
raphy (CT) scan of the chest, 2) WHO group II: PH second-
ary to left-sided heart disease: mPAP 25 mm Hg on RHC
with PCWP 15 mm Hg, and 3) WHO group III: PH sec-
ondary to chronic lung disease: mPAP 25 mm Hg on RHC
with PCWP 15 mm Hg with significant ILD, defined as an
FVC 65% predicted and/or moderate to severe ILD on
high-resolution CT.
Pre-PH patients can be recategorized as definite PH pa-
tients based on RHC over the course of the study; how-
ever, only 2 pre-PH patients had RHC-confirmed PH at 1
year of followup. The following information is collected
at baseline and at the annual followup: demographics,
medications, physical examination findings, New York
Heart Association (NYHA) functional classification assess-
ment, autoantibodies, BNP/NT-proBNP levels if avail-
able, pulmonary function tests, TTE results, findings on
high-resolution CT, 6-minute walk distance (6MWD), and
Significance & Innovations
● This is the first study to evaluate the construct
validity and responsiveness to change of the Uni-
versity of California in San Diego Shortness of
Breath Questionnaire (SOBQ) in systemic sclerosis
(SSc; scleroderma) patients with pulmonary vas-
cular disease.
● The SOBQ showed strong correlations with vali-
dated measures of disability, dyspnea, and health-
related quality of life in patients with SSc from
the Pulmonary Hypertension Assessment and Rec-
ognition of Outcomes in Scleroderma Registry.
● The SOBQ was responsive to change in compari-
son to the Health Assessment Questionnaire dis-
ability index and the Short Form 36 physical com-
ponent summary score.
● The SOBQ may have utility in predicting mortality
in patients with SSc-associated pulmonary hyper-
tension.
Utility of the UCSD Shortness of Breath Questionnaire 455
hemodynamics on RHC if performed. Outcomes including
hospitalizations for PH, deaths, and causes of deaths were
recorded at the time of the occurrence.
Every 6 months, patients completed the following ques-
tionnaires: the UCSD SOBQ, the Health Assessment Ques-
tionnaire (HAQ) disability index (DI) (14), and the Short
Table 1. Clinical characteristics of 179 subjects with systemic sclerosis*
Mean  SD or no. (%)
Demographic characteristics
Age, years 56  11
Female 155 (87)
Race
White, non-Hispanic 132 (74)





Disease duration, years (n  174) 10  11
FVC, % predicted (n  172) 79  18
DLCO, % predicted (n  171) 48  18
RVSP by echocardiogram, mm Hg (n  172) 45  17
Definite pulmonary hypertension 53 (30)
Group I PAH 38 (72)
Group II PVH 8 (15)
Group III ILD-PH 7 (13)
Health status measures












Distance, meters (n  133) 379  139
Borg dyspnea score (n 130) 2.3  2.0
12 months
Distance, meters (n  133) 365  141
Borg dyspnea score (n 130) 2.6  2.1
UCSD SOBQ (range 0–5)
Baseline 1.3  1.1
12 months 1.3  1.1
SHAQ
Baseline
HAQ DI total score (range 0–3) 0.9  0.8
Breathing VAS score (n  165) 0.9  0.9
12 months
HAQ DI total score (range 0–3) 0.9  0.8
Breathing VAS score (n  165) 0.8  0.8
SF-36 PCS score (range 0–100)
Baseline 34  12
12 months 35  12
SF-36 MCS score (range 0–100)
Baseline 49  11
12 months 49  11
* FVC  forced vital capacity; DLCO  diffusing capacity of carbon monoxide; RVSP  right ventricular
systolic pressure; PAH  pulmonary arterial hypertension; PVH  pulmonary venous hypertension;
ILD-PH  interstitial lung disease–associated pulmonary hypertension; NYHA  New York Heart Asso-
ciation; UCSD  University of California, San Diego; SOBQ  Shortness of Breath Questionnaire;
SHAQ  Scleroderma Health Assessment Questionnaire; HAQ  Health Assessment Questionnaire; DI 
disability index; VAS  visual analog scale; SF-36  Short Form 36 health survey; PCS  physical
component summary; MCS  mental component summary.
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Form 36 (SF-36) health survey. The UCSD SOBQ is com-
prised of 24 items that assess dyspnea over the preceding
week. There are 21 activity-based items that are scored on
a 6-point Likert scale, with 0 indicating no shortness of
breath and 5 indicating worst or unable to do secondary
to shortness of breath. In addition, patients rate 3 ques-
tions related to limitations secondary to dyspnea, fear of
harm from overexertion, and fear of shortness of breath.
The total score is reported as the mean of all items, with
0 indicating no dyspnea and 5 indicating severe dyspnea
(11). The minimum clinically important difference (MCID)
for the UCSD SOBQ has been estimated as a 5-unit change
on a summative scale of 0–120 (equivalent to a change
of 0.21 on our 0–5 scale, averaged across items) (15).
The HAQ DI includes 20 items in 8 functional domains
(dressing/grooming, arising, eating, walking, hygiene, reach,
grip, and activities), which assess the patient’s usual abil-
ities in the past 7 days. The overall score is calculated by
summing the highest item score in each of the domains
and dividing the sum by 8; the resulting score range is
0–3, where 0 indicates no disability and 3 indicates severe
disability. The scleroderma-specific version of the HAQ
(SHAQ) has 6 additional visual analog scales (VAS), which
assess the severity of pain, gastrointestinal symptoms,
shortness of breath, Raynaud’s phenomenon, digital ulcers,
and overall scleroderma disease activity in the past week.
The HAQ DI and the SHAQ have demonstrated reliability
and validity in assessing functional disability in patients
with SSc (16,17).
The SF-36 is a 36-item general health status instrument
assessing 8 domains: 1) limitations in physical activities
because of health problems; 2) limitations in social activ-
ities because of physical or emotional problems; 3) limita-
tions in usual role activities because of physical health
problems; 4) bodily pain; 5) general mental health (psy-
chological distress and well-being); 6) limitations in usual
role activities because of emotional problems; 7) vitality
(energy and fatigue); and 8) general health perceptions
(18). Two summary scores, the physical component sum-
mary (PCS) and the mental component summary, can be
determined, ranging from 0–100, with higher scores indi-
cating better health. The SF-36 has been used as a valid
measure of health status in observational studies and clin-
ical trials of patients with SSc (19–22).
For this analysis, we included only those subjects with
complete data for key self-reported measures (UCSD
SOBQ, HAQ DI, and SF-36) at baseline and at 12 months.
Pearson’s correlation coefficients were calculated to assess
convergent validity of the UCSD SOBQ in relation to the
HAQ DI, the breathing VAS of the SHAQ, the SF-36 PCS,
Table 2. Correlation matrix demonstrating construct validity of UCSD SOBQ relative to




















P  0.0001  0.0001
N 165 165
SF-36
r 0.77 0.73 0.60
P  0.0001  0.0001  0.0001
N 179 179 165
6MWD
r 0.33 0.40 0.24 0.35
P  0.0001  0.0001 0.0085  0.0001
N 133 133 123 133
Borg dyspnea score
r 0.47 0.35 0.46 0.37 0.29
P  0.0001  0.0001  0.0001  0.0001 0.0014
N 130 130 120 130 122
DLCO
r 0.33 0.18 0.31 0.26 0.18 0.13
P  0.0001 0.0171  0.0001 0.0006 0.0395 0.1541
N 171 171 157 171 127 125
* UCSD  University of California, San Diego; SOBQ  Shortness of Breath Questionnaire; HAQ  Health
Assessment Questionnaire; DI  disability index; SHAQ  Scleroderma Health Assessment Question-
naire; VAS  visual analog scale; SF-36  Short Form 36 health survey; PCS  physical component
summary; 6MWD  6-minute walk distance (meters); DLCO  diffusing capacity of carbon monoxide.
† Higher value indicates worse health status.
‡ Higher value indicates better health status.
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the 6MWD, the Borg dyspnea score, and the DLCO cor-
rected for hemoglobin measured at baseline. Correlations
of r  0.29 were considered to be weak, between r  0.30
and r  0.49 were moderate, and r  0.50 were strong (23).
Responsiveness to change of the UCSD SOBQ was as-
sessed in a similar manner relative to changes in these
same variables between baseline and 12 months. In addi-
tion, we calculated effect size, standardized response
means (SRMs), and responsiveness statistics for categori-
cal change in measures with reported MCID estimates
(6MWD, HAQ DI, and SF-36 PCS) (24–26). These indices
are ratios of observed change to a measure of variance,
also known as signal to noise. For all 3 indices, the nu-
merator is the mean change from the baseline to month 12
in the changed group and the denominators are the SD at
baseline (effect size), the SD of change for the changed
group (SRM), and the SD of change for people who are
deemed not to change (responsiveness statistics). Uni-
variate and multivariate (adjusting for age, sex, and race)
logistic regression models were developed to assess
whether the baseline UCSD SOBQ score is predictive of
death during study followup.
RESULTS
Baseline characteristics. Of 434 patients enrolled in
PHAROS at the time of this analysis, 179 had complete
data for self-reported outcomes of interest at baseline and
at 12 months. Baseline characteristics of our analysis
group are shown in Table 1. Mean  SD age was 56  11
years, 87% of patients were female, and 74% were white.
Sixty-one percent of the patients had limited cutaneous
disease, and the mean  SD disease duration from the time
of the first non–Raynaud’s phenomenon symptom was
10  11 years. Thirty percent of patients had definite PH
verified by RHC at baseline. The majority of subjects were
NYHA class I (43%) or class II (35%) at baseline, while
only 18% and 3% were class III and class IV, respectively.
The mean  SD UCSD SOBQ score at baseline was 1.3 
1.1. The mean  SD HAQ DI was 0.9  0.8, the mean  SD
breathing VAS score was 0.9  0.9, the mean  SD SF-36
PCS score was 34  12, the mean  SD 6MWD score was
379  139 meters, and the mean  SD Borg dyspnea score
was 2.3  2.0.
Figure 1. Discriminant validity of UCSD SOBQ by functional class and
presence of pulmonary hypertension. A, SOBQ scores by NYHA functional
class, P  0.0001 for trend, B, SOBQ scores in patients “at risk” for pulmo-
nary hypertension versus those with “definite” pulmonary hypertension,
P  0.0001. UCSD  University of California, San Diego; SOBQ  Shortness
of Breath Questionnaire; NYHA  New York Heart Association; PH 
pulmonary hypertension.
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Convergent validity. At baseline, the UCSD SOBQ
correlated in the expected direction with all measures
(Table 2). Higher UCSD SOBQ scores (greater dyspnea)
correlated strongly with worse disability as assessed by the
HAQ DI (r  0.71, P  0.0001) and more severe dyspnea
as measured by the SHAQ breathing VAS (r  0.71, P 
0.0001). Higher UCSD SOBQ scores also correlated
strongly with lower SF-36 PCS scores (worse physical
health status) (r  0.77, P  0.0001). There were moder-
ate correlations with poorer exercise capacity as assessed
by lower 6MWD scores (r  0.33, P  0.0001), greater
shortness of breath during exercise, as measured by the
Borg dyspnea score (r  0.47, P  0.0001), and lower DLCO
(r  0.33, P  0.0001).
Discriminant validity. UCSD SOBQ scores were able to
discriminate subjects according to NYHA functional clas-
sification status (Figure 1A). Mean  SD UCSD SOBQ
scores increased in a stepwise fashion for each increase in
NYHA functional class as follows: 0.8  0.9 for class I,
1.4  0.8 for class II, 2.2  0.9 for class III, and 3.4  0.8
for class IV (P  0.0001 for trend). Baseline UCSD SOBQ
scores were also able to discriminate between pre-PH and
definite PH patients with a higher mean score (greater
dyspnea) for those with definite PH (mean  SD 1.1  0.9
versus 1.9  1.4; P  0.0001) (Figure 1B).
Responsiveness to change. The mean  SD change in
UCSD SOBQ over 12 months was 0.06  0.73 in our
study. Using an MCID threshold of 0.21, 66 (37%) patients
demonstrated a meaningful improvement in the UCSD
SOBQ score and 50 (28%) patients demonstrated a mean-
ingful worsening in the UCSD SOBQ score. Change in the
UCSD SOBQ correlated in the expected direction with
change in the HAQ DI (r  0.54, P  0.0001) and change in
the SF-36 PCS (r  0.44, P  0.0001) (Table 3). There was
a weak correlation with change in the SHAQ breathing
VAS (r  0.18, P  0.025). No significant correlations were
found between change in the UCSD SOBQ and changes in
the 6MWD, Borg dyspnea score, or DLCO when assessed as
continuous variables. Estimates of effect size, SRMs, and
responsiveness statistics for categorical change in the
6MWD, the HAQ DI, and SF-36 PCS are shown in Table 4.
The UCSD SOBQ demonstrated evidence of good respon-
siveness with respect to other related patient-reported out-
comes, as indicated by effect size changes of 0.20 in
either direction. The UCSD SOBQ was only minimally
responsive to improvement in the 6MWD and was not
responsive to worsening in the 6MWD, as indicated by
effect size changes of 0.20. Similar patterns of respon-
siveness were observed for SRMs and responsiveness sta-
tistics.
Table 3. Correlation matrix demonstrating longitudinal construct validity of UCSD SOBQ in conceptually related health status
measures over 12 months*
 UCSD SOBQ  SHAQ total†
 Breathing
VAS†  SF-36 PCS‡  6MWD‡
 Borg
dyspnea score†
 UCSD SOBQ –









r 0.44 0.36 0.23
P  0.0001  0.0001 0.004
N 179 179 162
 6MWD –
r 0.12 0.11 0.19 0.09
P 0.25 0.31 0.09 0.43
N 86 86 77 86
 Borg –
r 0.20 0.09 0.001 0.001 0.19
P 0.06 0.42 0.99 0.99 0.11
N 84 84 75 84 75
 DLCO
r 0.03 0.03 0.30 0.04 0.04 0.02
P 0.7654 0.7602 0.0025 0.6990 0.7329 0.8875
N 112 112 97 112 70 64
* UCSD  University of California, San Diego; SOBQ  Shortness of Breath Questionnaire; SHAQ  Scleroderma Health Assessment Questionnaire;
VAS  visual analog scale; SF-36  Short Form 36 health survey; PCS  physical component summary; 6MWD  6-minute walk distance (meters);
HAQ  Health Assessment Questionnaire; DI  disability index; DLCO  diffusing capacity of carbon monoxide.
† Higher value indicates worse health status.
‡ Higher value indicates better health status.
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Predictive validity. A higher UCSD SOBQ score at base-
line was associated with a greater risk of death during
study followup, but this was not statistically significant in
univariate analysis (odds ratio [OR] 1.57, 95% confidence
interval [95% CI] 0.90–2.72) (Table 5). Multivariate analy-
sis adjusting for age, sex, and race identified male sex as
a significant predictor of death (OR 7.00, 95% CI 1.55–
31.76), while the UCSD SOBQ showed a strong trend to-
ward significance (OR 1.82, 95% CI 0.97–3.41).
DISCUSSION
When considering the validation of a new measure or
descriptor to be used in clinical trials, one needs to con-
sider its feasibility, its face, content, construct, and crite-
rion validity, and discrimination, including its reliability
and sensitivity to change, as described through the Out-
come Measures in Rheumatology organization (27,28).
Feasibility measures how easily an index can be applied
with regards to cost, time, and interpretability (27). Face
validity refers to whether a measure appears to measure at
least one aspect of the reference condition, while content
validity is a measure of the comprehensiveness of the
measure (28). Construct validity involves comparing the
index score of interest against those derived from other
validated indices, while criterion validity involves com-
parison to a gold standard (28). Reliability encompasses
internal consistency, test–retest consistency or stability
over time (intrarater reliability), and agreement between
observers (interrater reliability) (28).
Sensitivity to change measures the responsiveness of an
index to change over time. In this study we provide pre-
liminary validation of the UCSD SOBQ as a measure of
dyspnea in SSc patients at high risk of or with incident PH.
The UCSD SOBQ demonstrated good construct validity
with strong correlations in the expected directions with
disability, dyspnea assessment by VAS, and physical
health status, and a moderate correlation with exercise
capacity and DLCO. The UCSD SOBQ also demonstrated
good discriminative properties by differentiating among
subgroups of patients stratified according to NYHA func-
tional classifications and pre- versus definite PH status.
Responsiveness to change was demonstrated with moder-
ate to strong correlations in the expected directions with
measures of physical health status (i.e., SF-36 PCS) and
disability (i.e., HAQ DI), which was also further supported
by calculated responsiveness indices. The lack of respon-
siveness to the 6MWD is not surprising as the 6MWD is
confounded by musculoskeletal involvement and decon-
ditioning in SSc. Finally, predictive validity of the UCSD
SOBQ was suggested by a nonsignificant (P  0.06) trend
indicating a 1.8-fold increased risk of death per 1-point
increase in dyspnea score at baseline.
Patient-reported outcome instruments are increasingly
recognized as important tools for assessing disease sever-
ity and response to therapy. Measures of dyspnea may be
particularly important in SSc, but the performance char-
Table 5. Predictive validity of the UCSD SOBQ based on
relative risk of death during study followup*
Predictor OR (95% CI) P
Univariate model
UCSD SOBQ 1.57 (0.90–2.72) 0.11
Age 1.07 (0.99–1.14) 0.07
Male 4.97 (1.29–19.13) 0.02
White, non-Hispanic 3.37 (0.42–27.31) 0.26
Multivariate model
UCSD SOBQ 1.82 (0.97–3.41) 0.06
Age 1.07 (0.99–1.16) 0.07
Male 7.00 (1.55–31.76) 0.01
White, non-Hispanic 1.83 (0.19–17.28) 0.60
* UCSD  University of California, San Diego; SOBQ  Shortness of
Breath Questionnaire; OR  odds ratio; 95% CI  95% confidence
interval.
Table 4. Responsiveness of UCSD SOBQ for categorical change in 6MWD, HAQ DI, and SF-36*
Referent measure N
Change in UCSD





ES SRM RS ES SRM RS
Change in 6MWD 0.12 0.21 0.15 0.03 0.05 0.03
40 meter improvement 22 0.13  0.62
No meaningful change 38 0.09  0.86 0.53
40 meter worsening 26 0.03  0.61
Change in HAQ DI
0.14 point improvement 47 0.54  0.76 0.50 0.71 1.08 0.22 0.30 0.48
No meaningful change 85 0.04  0.50  0.0001
0.14 point worsening 47 0.24  0.81
Change in SF-36 PCS
2.0 point improvement 70 0.25  0.64 0.23 0.39 0.32 0.24 0.38 0.33
No meaningful change 51 0.16  0.78 0.0001
2.0 point worsening 58 0.26  0.68
* UCSD  University of California, San Diego; SOBQ  Shortness of Breath Questionnaire; 6MWD  6-minute walk distance (meters); HAQ  Health
Assessment Questionnaire; DI  disability index; SF-36  Short Form 36 health survey; ES  effect size; SRM  standardized response mean; RS 
responsiveness statistic; PCS  physical component summary.
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acteristics of these different instruments need further eval-
uation. In a cohort of unselected SSc patients from Canada,
dyspnea as assessed on an 11-point numerical rating scale
had a moderate correlation with the HAQ DI and SF-36
PCS (Kendall’s   0.30 and   0.46, respectively, P 
0.001 for both) (29). A recent study of SSc patients fol-
lowed at Northwestern University found strong correla-
tions between the Functional Assessment of Chronic Ill-
ness Therapy (dyspnea) and dyspnea-related functional
limitation scores and the HAQ DI (r  0.64 and r  0.76,
respectively) (30). Another study showed moderate corre-
lations in the expected directions between functional dis-
ability and 2 measures of breathlessness, the Mahler’s
baseline dyspnea index (BDI) (r  0.33, P  0.01) and
the breathing VAS on the SHAQ (r  0.46, P  0.01), in
patients with SSc-ILD (20). This study also found strong
correlations in the expected directions between these 2
dyspnea scales and the SF-36 PCS (r  0.51 and r  0.59
for the BDI and the VAS, respectively, P  0.01 for both)
(20).
We chose the UCSD SOBQ for our study since this
instrument focuses on dyspnea alone rather than health-
related quality of life or functional capacity, which are
already measured by the SF-36 and the HAQ DI. Our study
found strong correlations between the UCSD SOBQ and
disability and physical health status in SSc patients at
high risk of or with incident PH (r  0.71 and r  0.77,
respectively). A small study in 28 patients with SSc and
restrictive lung disease found a strong inverse correlation
between the Saint George’s Respiratory Questionnaire and
the 6MWD (r  0.77, P  0.0001) (31). Similarly, our
study also found an inverse correlation between the UCSD
SOBQ and 6MWD; however, the strength of correlation
was not as robust (r  0.33).
The UCSD SOBQ was originally developed for use in the
pulmonary rehabilitation setting and has been used exten-
sively in studies of chronic obstructive pulmonary disease
(COPD) (11). Mean scores in patients with moderately
severe COPD are typically in the mid-50s on a scale of
0–120 (approximately 2.3 on the scale used in this study)
(15,32). A recent study in patients with CTD-ILD found a
mean SOBQ score of 46 out of 120 (equivalent to 1.9 on the
scale used in this study) (13). Our study is the first to
evaluate the utility of the SOBQ in SSc patients with
pulmonary vascular disease. The mean  SD UCSD SOBQ
score in the PHAROS cohort was lower (1.3  1.1) than the
CTD-ILD population in the Swigris et al study, which is
consistent with less severe dyspnea despite similar pul-
monary function (mean FVC 72% in CTD-ILD versus 79%
predicted in PHAROS patients and mean DLCO 52% in
CTD-ILD versus 48% predicted in PHAROS patients) (13).
The low UCSD SOBQ scores may reflect the inclusion of a
large proportion of patients in classes I and II in the
PHAROS registry related to the routine screening and early
detection of PH in this cohort. Similar to our findings,
Swigris et al showed a strong correlation between the
UCSD SOBQ and functional disability (r  0.58, P 
0.0001), as well as lower DLCO (r  0.53, P  0.004) in
patients with CTD-ILD (13). Although dyspnea may be
qualitatively different among these different pulmonary
disease states due to differences in the underlying patho-
physiology, the UCSD SOBQ quantifies dyspnea-related
activity limitations, which are likely similar among differ-
ent pulmonary conditions.
To our knowledge, our study was also the first to assess
the responsiveness to change of a dyspnea scale in a pro-
spective longitudinal cohort of SSc patients with pulmo-
nary disease. Although the mean SOBQ score across the
entire study cohort remained relatively unchanged, 37%
of patients improved and 28% of patients worsened by the
MCID at 12 months. We found moderate to strong correla-
tions in the change of the UCSD SOBQ with change in
SF-36 PCS and HAQ DI, but no significant correlation with
change in 6MWD or Borg dyspnea scores. When evaluating
the 6MWD as a categorical variable using the MCID of 40
meters as a cut point (24), the mean improvement in UCSD
SOBQ was 0.22, slightly greater than the MCID of 0.21, but
this was not statistically significant. These findings were
not unexpected and are consistent with the fact that dys-
pnea as assessed by the UCSD SOBQ represents a distinct
construct from walk test parameters obtained under artifi-
cially imposed conditions. Notably, the UCSD SOBQ may
be less confounded by musculoskeletal disease, and there-
fore may be a more accurate reflection of cardiopulmonary
status in SSc patients than the 6MWD. In addition, the
UCSD SOBQ provides a more comprehensive assessment
of dyspnea than the Borg dyspnea score, which asks for a
single rating of breathlessness immediately after exercise.
The change in UCSD SOBQ also did not correlate with
change in DLCO at 12 months, suggesting that lung func-
tion and subjective symptoms may change at different
rates in SSc patients at high risk of or with incident PH.
This is not unexpected given the overall slow decline in
DLCO observed in patients with SSc-ILD (33).
Our study also evaluated the predictive validity of the
UCSD SOBQ on mortality in the PHAROS cohort. Male sex
was an independent predictor of death, in agreement with
other survival studies in patients with SSc (34,35). There
was a strong trend indicating an association between
higher baseline UCSD SOBQ scores and death during
study followup. Given that there were only 10 deaths
recorded, confirmation of the predictive value of the UCSD
SOBQ with respect to death in SSc-PH patients will re-
quire a longer observation period in a larger cohort of
patients with definite PH.
As with all registry studies, our study was limited by
missing data, particularly with respect to 6MWD and Borg
dyspnea scores. This may have limited our ability to detect
smaller correlations between these variables and the UCSD
SOBQ. We did not assess for correlations with RVSP or
hemodynamic parameters given the poor predictive value
of these measures in patients with SSc-PAH compared
with those with idiopathic disease (5,36). We were also
unable to assess correlations between the UCSD SOBQ and
BNP/NT-proBNP levels because of inadequate laboratory
data. All of the centers involved in PHAROS are sclero-
derma centers at which routine screening for PAH with
annual pulmonary function tests and TTEs is performed.
Therefore, our results may not be generalizable to SSc-PH
populations followed in the general community. Finally,
responsiveness to change analyses were limited by the
short followup period and the modest proportion of pa-
tients meeting criteria for minimal change.
In conclusion, we have shown that the UCSD SOBQ
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demonstrates acceptable measurement properties in SSc
patients with pulmonary vascular disease. Specifically, it
converges with related constructs in the anticipated man-
ner and appears to be responsive to changes in related
measures of health status. Our study provides evidence
that the UCSD SOBQ is a potentially useful measure of
disease severity and progression that provides comple-
mentary information in addition to the 6MWD in SSc
patients at high risk of and with PAH.
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